Skip to main content
. 2017 May 30;17:71. doi: 10.1186/s12911-017-0475-8

Fig. 1.

Fig. 1

Algorithm for intended use of EGFR and proteomic testing in NSCLC patients. For clarity, various algorithms of chemotherapy and targeted treatments other than erlotinib were not included